Board of Directors
Kevin J. Dallas has served as a director of Align Technology, Inc. since May 2018. In his current role at Microsoft Corporation (NASDAQ: MSFT), Mr. Dallas is Corporate Vice President, Artificial Intelligence & Intelligent Cloud Business Development.
At Microsoft, his team creates partnerships that help enable the digital transformation of customers and partners across a range of industries including: connected/autonomous vehicles, industrial IoT, discrete manufacturing, retail, financial services, media and entertainment, and healthcare. With advanced technologies that include intelligent cloud and intelligent edge services, Microsoft enables business outcomes that include: transforming products, optimizing operations, empowering employees, and enhancing customer engagement.
Prior to joining Microsoft in 1996, Mr. Dallas held roles at NVIDIA Corporation and National Semiconductor (now Texas Instruments Inc.) in the U.S., Europe and the Middle East in roles that included microprocessor design, systems engineering, product management, and end-to-end business leadership. He holds an Executive M.B.A. from the Kellogg School of Management at Northwestern University, and a B.S. degree in Computer Science from Staffordshire University, Stoke-on-Trent, Staffordshire, England.
Joseph Lacob has served as a director of Align Technology since August 1997 and has been a partner of Kleiner Perkins Caufield & Byers (KPCB), a venture capital firm, since May 1987. In 2011, Mr. Lacob acquired The Golden State Warriors of the National Basketball Association. He is currently the Managing Partner and CEO of the Warriors. Prior to joining KPCB in 1987, Mr. Lacob was an executive with Cetus Corporation (now Chiron), FHP International, a health maintenance organization (HMO), and the management consulting firm of Booz, Allen & Hamilton. Since joining KPCB in 1987, Mr. Lacob has been closely involved with KPCB's investments in more than 50 life science companies, including the startup or incubation of a dozen ventures, and with KPCB's medical technology practice, which includes more than 30 therapeutic and diagnostic medical device companies. He was previously on the board of directors of Orexigen Therapeutics, a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Mr. Lacob received his B.S. degree in Biological Sciences from the University of California at Irvine, his Masters degree in Public Health from the University of California at Los Angeles and his M.B.A. from Stanford University
C. Raymond Larkin, Jr., has served as a director of Align Technology since March 2004. In February 2006, Mr. Larkin was appointed as Chairman of the Board. He currently serves as a principal of Group Outcome L.L.C., a merchant banking firm concentrating on medical technologies. From 2001 to 2007, he served as a part time Venture Partner at Cutlass Capital, a venture capital firm. Prior to Group Outcome, Mr. Larkin was Chairman and CEO at Eunoe Inc., an investigative device for slowing and stopping progression of Alzheimer's disease. Prior to that, he was President and Chief Executive Officer of Nellcor Puritan Bennett, Inc., one of the world's preeminent respiratory products companies. Under Mr. Larkin's leadership over 15 years, Nellcor grew to nearly $1 billion in revenues through the development and introduction of pulse oximetry into worldwide use for patient safety monitoring, setting the standard of care for the respiratory-impaired patient. Mr. Larkin also held positions of increasing responsibility at Bentley Laboratories/American Hospital Supply from 1976 to 1983. He serves on the board of directors of Heartware, Inc., a medical device company developing implant devices for the treatment of advanced heart failure. Mr. Larkin received his B.S. degree in Industrial Management from LaSalle University.
George J. Morrow has served as a director of Align Technology since February 2006. From February 2011 until January 2013, Mr. Morrow served as a consultant to Amgen Inc., a global biotechnology company. From 2003 until his retirement in February 2011, he was the Executive Vice President, Global Commercial Operations at Amgen Inc., where he also served as Executive Vice President of Worldwide Sales and Marketing between 2001 and 2003. From 1992 to 2001, Mr. Morrow held multiple leadership positions at GlaxoSmithKline Inc. and its subsidiaries, including President and Chief Executive Officer of Glaxo Wellcome Inc. He is a member of the board of directors of Vical Incorporated, a company that researches and develops biopharmaceutical products, Safeway Inc., a food and drug retailer and was a member of the board of directors of Human Genome Sciences, Inc., a biopharmaceutical discovery and development company, from March 2011 until its acquisition in August 2012 by GlaxoSmithKline plc. Mr. Morrow holds a B.S. degree in Chemistry from Southampton College, Long Island University, a M.S. degree in Biochemistry from Bryn Mawr College and an M.B.A. from Duke University.
Anne Myong was appointed to Align’s Board of Directors in August 2019. Ms. Myong was previously Senior Vice President and Chief Financial Officer at Walmart Global eCommerce, where she accelerated the growth and digital transformation of Walmart’s retail and e-commerce operations in the United States, China and Brazil. Earlier, she was Senior Vice President, Chief Financial and Administrative Officer, Walmart China Retail. In that role, she was the senior operations and finance executive leading a retail operation of over 400 stores and 100,000 associates across China. Prior to her roles at Walmart, Ms. Myong was Vice President and CFO of Agilent Technologies China, where she was the senior finance executive of Agilent’s fastest growing and second largest market.
Since 2016, Ms. Myong has been a board member at Goodwill Industries International.
Ms. Myong holds an M.B.A. degree from Harvard Business School and a B.B.A. degree in Computer Information Systems from James Madison University.
Thomas M. Prescott served as President, Chief Executive Officer (CEO), and a Director of Align Technology from March 2002 through May 2015. In June 2015, Mr. Prescott retired as President and CEO while continuing to serve on the Board of Directors.
From May 1999 to August 2001, he was the President, CEO and a Director of Cardiac Pathways, a pioneer in treating dangerous cardiac arrhythmias with cooled ablation technology. Mr. Prescott led the turnaround, recapitalization and ultimately the sale of this interventional cardiology company to Boston Scientific Corporation.
Prior to Cardiac Pathways, Prescott held various general management and executive roles at Nellcor Puritan Bennett, a company with nearly $1B in revenue as a leader in respiratory products and pioneer of pulse oximetry for patient safety monitoring. Prescott also held various management positions at GE Medical Systems, a global leader in diagnostic imaging and transformational medical technologies. In addition, he served in sales, marketing and management roles at Siemens, one of the world’s largest electrical engineering and electronics companies. He earned his Master’s degree from Kellogg Graduate School of Management, Northwestern University and his Bachelor’s degree in Civil Engineering from Arizona State University.
Andrea L. Saia has served as a director of Align Technology since July 2013. Ms. Saia has extensive global experience within the healthcare, medical device and consumer products industries. Ms. Saia was previously the Global Head of Vision Care in the Alcon division of Novartis AG. Prior to this role, she served as President and Chief Executive Officer of CibaVision Corporation, a +$2Bio subsidiary of Novartis, from 2008 to 2011. From 2005 to 2007, she served as President of Europe, Middle East, and Africa operations, the company’s largest regional business unit. She initially joined CibaVision in 2002 as Global Head of Marketing and was promoted to President of the Global Lens Business the following year. Prior to Novartis, Ms. Saia was the Chief Marketing Officer for venture capital firm GCG Partners Inc. Ms. Saia also held senior management and marketing positions with global consumer products companies such as Procter & Gamble, Unilever, and Revlon. Ms. Saia earned an M.B.A. degree from J.L. Kellogg Graduate School of Business and a B.S. degree in Business Administration from Miami University. Ms. Saia also serves on the board of directors of medical devices company LivaNova PLC and also served on the board of Coca-Cola Enterprises, Inc., the marketer, producer and distributor of Coca-Cola products in European markets. She is a member of the National Association of Corporate Directors, Women Corporate Directors and the Signature Program. Andrea serves on the Advisory Board of the Farmer Business School at Miami University.
Greg J. Santora has server as a director of Align Technology since July 2003. From 2003 through 2005, Mr. Santora served as the Chief Financial Officer for Shopping.com, a provider of Internet-based comparison shopping resources. From 1997 through 2002, Mr. Santora was the Chief Financial Officer and Senior Vice President for Intuit Inc.. a provider of small business and personal finance software. Prior to Intuit, he spent 13 years at Apple Computer in various senior financial positions including Senior Finance Director of Apple Americas and Senior Director of Internal Consulting and Audit. Mr. Santora began his accounting career with Arthur Andersen L.L.P., and has been a CPA since 1974. Mr. Santora also serves on the board of directors and is Audit Committee Chairman of RetailMeNot, Inc. He serves on the board of directors of RetailMeNot, Inc., a digital coupon site, since May 2013. In addition, he served on the board of directors of Taleo Corporation, a provider of on-demand talent management solutions until its acquisition by Oracle Corporation in April 2012. Mr. Santora holds a B.S. degree in Accounting from the University of Illinois and an M.B.A. from San Jose State University.
Susan (Sue) E, Siegel was elected as a director of Align in May 2017. Since 2012, Ms. Siegel has been CEO of GE Ventures, General Electric’s growth and innovation business. Ms. Siegel has 30+ years of experience within corporate companies and venture capital firms. Prior to GE Ventures, Ms. Siegel was a General Partner at Mohr Davidow Ventures, where she led investments in personalized medicine, digital health, and life sciences. Before venture capital, she served as president and board member at Affymetrix and drove the company’s transformation from a pre-revenue start up to a global, multi-billion dollar market cap genomics leader. Prior to Affymetrix, Ms. Siegel led strategy, technology development, licensing, manufacturing, as well as new market creation & development at Bio-Rad, DuPont, and Amersham. Ms. Siegel holds a M.S. in Biochemistry and Molecular Biology from Boston University Medical School and a B.S. in Biology from the University of Puerto Rico. She currently serves on the boards of the National Venture Capital Association, MIT’s The Engine, RAND Health, Stanford Medicine’s Board of Leaders, University of California’s Innovation Council, Harvard Partners’ Innovation Advisory Board, and USC’s Schaeffer Center for Health Policy. She is an Aspen Institute Crown Fellow.
Warren Thaler has served as a director of Align Technology since June 2004. Since 2001, Mr. Thaler has been President of Gund Investment Corporation, an investment firm owned by Gordon Gund with holdings in real estate as well as public and private equity securities. Since 1990, Mr. Thaler has served on the boards of several privately held companies owned by the Gund family. From 1990 to 2005, Mr. Thaler was on the board of directors of the Cleveland Cavaliers and Gund Arena Company and from 2001 to 2005 represented the Cleveland Cavaliers as its Alternate Governor at meetings of the National Basketball Association's Board of Governors. Mr. Thaler received his B.A. degree from Princeton University and his M.B.A. from Harvard University.